TGF-β and EGF induced HLA-I downregulation is associated with epithelial-mesenchymal transition (EMT) through upregulation of snail in prostate cancer cells

Molecular Immunology

Volumn 65, Issue 1, 2015, Pages 34-42

  Chen, Xiao Hui ^a   Liu, Zong Cai ^a   Zhang, Ge ^a   Wei, Wei ^a   Wang, Xiao Xiong ^b   Wang, Hao ^a   Ke, Hong Peng ^a   Zhang, Fan ^a   Wang, Hong Sheng ^a   Cai, Shao Hui ^b   Du, Jun ^a  

^a SUN YAT SEN UNIVERSITY   (China)

^b JINAN UNIVERSITY   (China)

Author keywords

Epithelial mesenchymal transition (EMT); HLA I; Immune escape; Prostate cancer; Snail

Indexed keywords

FAS ANTIGEN; HLA ANTIGEN CLASS 1; HLA B ANTIGEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 2; PROTEIN BAX; PROTEIN BCL 2; RECOMBINANT EPIDERMAL GROWTH FACTOR; RECOMBINANT TRANSFORMING GROWTH FACTOR BETA; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR SNAIL; EPIDERMAL GROWTH FACTOR; RELA PROTEIN, HUMAN; SNAIL FAMILY TRANSCRIPTION FACTORS; TRANSCRIPTION FACTOR RELA; TRANSFORMING GROWTH FACTOR BETA;

ARTICLE; CD8+ T LYMPHOCYTE; CELL STRUCTURE; CLINICAL EVALUATION; CONTROLLED STUDY; CYTOLYSIS; CYTOTOXIC T LYMPHOCYTE; DISEASE ASSOCIATION; DOWN REGULATION; ENZYME MECHANISM; EPITHELIAL MESENCHYMAL TRANSITION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOSURVEILLANCE; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROSTATE CANCER CELL LINE; PROTEIN EXPRESSION; UPREGULATION; BIOSYNTHESIS; GENETIC TRANSCRIPTION; GENETICS; IMMUNOLOGY; PROSTATE TUMOR; RNA INTERFERENCE; TUMOR CELL LINE; TUMOR ESCAPE;

GASTROPODA;

CELL LINE, TUMOR; DOWN-REGULATION; EPIDERMAL GROWTH FACTOR; EPITHELIAL-MESENCHYMAL TRANSITION; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; MALE; PROSTATIC NEOPLASMS; RNA INTERFERENCE; RNA, SMALL INTERFERING; T-LYMPHOCYTES, CYTOTOXIC; TRANSCRIPTION FACTOR RELA; TRANSCRIPTION FACTORS; TRANSCRIPTION, GENETIC; TRANSFORMING GROWTH FACTOR BETA; TUMOR ESCAPE; UP-REGULATION;

EID: 84921496970     PISSN: 01615890     EISSN: 18729142     Source Type: Journal    
DOI: 10.1016/j.molimm.2014.12.017     Document Type: Article

References (41)

1. Ahmad S., Sweeney P., Sullivan G.C., Tangney M. DNA vaccination for prostate cancer, from preclinical to clinical trials-where we stand?. Genet. Vaccine Ther. 2012, 1(10).
2. Akalay I., Janji B., Hasmim M., Noman M.Z., André F., De Cremoux P., Bertheau P., Badoual C., Vielh P., Larsen A.K., Sabbah M., Tan T.Z., Keira J.H., Ying Hung N.T., Thiery J.P., Mami-Chouaib F., Chouaib S. Epithelial-to-mesenchymal transition and autophagy induction in breast carcinoma promote escape from T-cell-mediated lysis. Cancer Res. 2013, 73(8):2418-2427. 10.1158/0008-5472.can-12-2432.
3. Aptsiauri N., Cabrera T., Mendez R., Garcia-Lora A., Ruiz-Cabello F., Garrido F. Role of altered expression of HLA class I molecules in cancer progression. Adv. Exp. Med. Biol. 2007, 601:123-131.
4. Arlen P.M., Wood L.V. Prostate cancer vaccines: moving therapeutic vaccination forward in the post-Provenge™ era. Expert Rev. Vaccines 2012, 11(3):287-302. 10.1586/erv.11.183.
5. Blades RA, Keating PJ, McWilliam LJ, George NJR, Stern P.L. Loss of HLA class I expression in prostate cancer: implications for immunotherapy. Urology 1995, 46(5):681-687. http://dx.doi.org/10.1016/S0090-4295(99)80301-X.
6. Bukur J., Jasinski S., Seliger B. The role of classical and non-classical HLA class I antigens in human tumors. Semin. Cancer Biol. 2012, 22(4):350-358. DOI S1044-579X(12)00052-1 [pii].10.1016/j.semcancer.2012.03.003.
7. Coffey D., Isaacs J. Control of prostate growth. Urol. Suppl. 1981, 3(17):17-24.
8. Darrow T.L., Slingluff C.L., Seigler H.F. The role of HLA class I antigens in recognition of melanoma cells by tumor-specific cytotoxic T lymphocytes evidence for shared tumor antigens. J. Immunol. 1989, 142(9):3329-3335.
9. Fang X., Thornton C., Scheffler B.E., Willett K.L. Benzo[a]pyrene decreases global and gene specific DNA methylation during zebrafish development. Environ. Toxicol. Pharmacol. 2013, 36(1):40-50. DOI S1382-6689(13)00030-6 [pii].10.1016/j.etap.2013.02.014.
10. Garcia-Lora A., Algarra I., Garrido F. MHC class I antigens, immune surveillance, and tumor immune escape. J. Cell. Physiol. 2003, 195(3):346-355. DOI 10.1002/jcp.10290.
11. Ge L.C., Chen Z.J., Liu H.Y., Zhang K.S., Liu H., Huang H.B., Zhang G., Wong C.K.C., Giesy J.P., Du J., Wang H.S. Involvement of activating ERK1/2 through G protein coupled receptor 30 and estrogen receptor alpha/beta in low doses of bisphenol A promoting growth of Sertoli TM4 cells. Toxicol. Lett. 2014, 226(1):81-89. DOI 10.1016/j.toxlet.2014.01.035.
12. Girdlestone J., Isamat M., Gewert D., Milstein C. Transcriptional regulation of HLA-A and -B: differential binding of members of the Rel and IRF families of transcription factors. Proc. Natl. Acad. Sci. U.S.A. 1993, 90(24):11568-11572.
13. Gobin S.J., Keijsers V., van Zutphen M., van den Elsen P.J. The role of enhancer A in the locus-specific transactivation of classical and nonclassical HLA class I genes by nuclear factor kappa B. J. Immunol. 1998, 161(5):2276-2283.
14. Gorelik L., Flavell R.A. Transforming growth factor-beta in T-cell biology. Nat. Rev. Immunol. 2002, 2(1):46-53. DOI 10.1038/Nri704.
15. Harada M., Noguchi M., Itoh K. Target molecules in specific immunotherapy against prostate cancer. Int. J. Clin. Oncol. 2003, 8(4):193-199. DOI 10.1007/s10147-003-0332-x.
16. Hicklin D.J., Marincola F.M., Ferrone S. HLA class I antigen downregulation in human cancers: T-cell immunotherapy revives an old story. Mol. Med. Today 1999, 5(4):178-186. DOI S1357-4310(99)01451-3[pii].
17. Kawakami M., Nakayama J. Enhanced expression of prostate-specific membrane antigen gene in prostate cancer as revealed by in situ hybridization. Cancer Res. 1997, 57(12):2321-2324.
18. Kudo-Saito C., Shirako H., Takeuchi T., Kawakami Y. Cancer metastasis is accelerated through immunosuppression during Snail-Induced EMT of cancer cells. Cancer Cell 2009, 15(3):195-206. http://dx.doi.org/10.1016/j.ccr.2009.01.023.
19. Le Bouteiller P. HLA class I chromosomal region, genes, and products: facts and questions. Crit. Rev. Immunol. 1994, 14(2):89-129.
20. Liu Z-c, Chen X-h, Song H-x, Wang H-s, Zhang G., Wang H., Chen D-y, Fang R., Liu H., Cai S-h, Du J. Snail regulated by PKC/GSK-3β pathway is crucial for EGF-induced epithelial-mesenchymal transition (EMT) of cancer cells. Cell Tissue Res. 2014, 358(2):491-502. DOI 10.1007/s00441-014-1953-2.
21. Liu Z-c, Wang H-s, Zhang G., Liu H., Chen X-h, Zhang F., Chen D-y, Cai S-h, Du J. AKT/GSK-3β regulates stability and transcription of snail which is crucial for bFGF-induced epithelial-mesenchymal transition of prostate cancer cells. Biochim. Biophys. Acta (BBA) - Gen. Subjects 2014, 1840(10):3096-3105. http://dx.doi.org/10.1016/j.bbagen.2014.07.018.
22. Lyons J.G., Patel V., Roue N.C., Fok S.Y., Soon L.L., Halliday G.M., Gutkind J.S. Snail up-regulates proinflammatory mediators and inhibits differentiation in oral keratinocytes. Cancer Res. 2008, 68(12):4525-4530. DOI 10.1158/1078-0432.ccr-07-6735.
23. Mansky P., Brown W.M., Park J.H., Choi J.W., Yang S.Y. The second kappa B element, kappa B2, of the HLA-A class I regulatory complex is an essential part of the promoter. J. Immunol. 1994, 153(11):5082-5090.
24. Michael Z., Eric G.N. Biomarkers for epithelial-mesenchymal transitions. J. Clin. Investig. 2009, 119(6):1429-1437.
25. Moitreyee C.K., Suraksha A., Swarup A.S. Potential role of NF-kB and RXR beta like proteins in interferon induced HLA class I and beta globin gene transcription in K562 erythroleukaemia cells. Mol. Cell. Biochem. 1998, 178(1-2):103-112.
26. Nieto M.A. The snail superfamily of zinc-finger transcription factors. Nat. Rev. Mol. Cell Biol. 2002, 3(3):155-166.
27. Peinado H., Olmeda D., Cano A. Snail Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype?. Nat. Rev. Cancer 2007, 7(6):415-428.
28. Prendergast G.C. Immune escape as a fundamental trait of cancer: focus on IDO. Oncogene 2008, 27(28):3889-3900.
29. Rabinovich G.A., Gabrilovich D., Sotomayor E.M. Immunosuppressive strategies that are mediated by tumor cells. Annu. Rev. Immunol. 2007, 25(1):267-296. DOI 10.1146/annurev.immunol.25.022106.141609.
30. Salomon D.S., Brandt R., Ciardiello F., Normanno N. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit. Rev. Oncol./Hematol. 1995, 19(3):183-232. http://dx.doi.org/10.1016/1040-8428(94)00144-I.
31. Seliger B., Cabrera T., Garrido F., Ferrone S. HLA class I antigen abnormalities and immune escape by malignant cells. Semin. Cancer Biol. 2002, 12(1):3-13. http://dx.doi.org/10.1006/scbi.2001.0404.
32. Siegel R., DeSantis C., Virgo K., Stein K., Mariotto A., Smith T., Cooper D., Gansler T., Lerro C., Fedewa S., Lin C., Leach C., Cannady R.S., Cho H., Scoppa S., Hachey M., Kirch R., Jemal A., Ward E. Cancer treatment and survivorship statistics, 2012. CA: Cancer J. Clin. 2012, 62(4):220-241. DOI 10.3322/caac.21149.
33. Smith B.N., Odero-Marah V.A. The role of Snail in prostate cancer. Cell Adhes. Migration 2012, 6(5):433-441.
34. Thiery J.P., Acloque H., Huang R.Y.J., Nieto M.A. Epithelial-mesenchymal transitions in development and disease. Cell 2009, 139(5):871-890. http://dx.doi.org/10.1016/j.cell.2009.11.007.
35. Ting J.P., Baldwin A.S. Regulation of MHC gene expression. Curr. Opin. Immunol. 1993, 5(1):8-16.
36. Tomas A., Futter C.E., Eden E.R. EGF receptor trafficking: consequences for signaling and cancer. Trends Cell Biol. 2014, 24(1):26-34. DOI S0962-8924(13)00193-1[pii].10.1016/j.tcb.2013.11.002.
37. Uttamsingh S., Bao X., Nguyen K.T., Bhanot M., Gong J., Chan J.L.K., Liu F., Chu T.T., Wang L.H. Synergistic effect between EGF and TGF-[beta]1 in inducing oncogenic properties of intestinal epithelial cells. Oncogene 2007, 27(18):2626-2634. http://www.nature.com/onc/journal/v27/n18/suppinfo/1210915s1.html.
38. Venkataraman G.M., Suciu D., Groh V., Boss J.M., Spies T. Promoter region architecture and transcriptional regulation of the genes for the MHC class I-related chain A and B ligands of NKG2D. J. Immunol. 2007, 178(2):961-969. DOI 178/2/961 [pii].
39. Wikström P., Stattin P., Franck-Lissbrant I., Damber J.-E., Bergh A. Transforming growth factor β1 is associated with angiogenesis, metastasis, and poor clinical outcome in prostate cancer. The Prostate 1998, 37(1):19-29. DOI 10.1002/(sici)1097-0045(19980915)37:1<19::aid-pros4>3.0.co;2-3.
40. Wu Y., Deng J., Rychahou P.G., Qiu S., Evers B.M., Zhou B.P. Stabilization of Snail by NF-kB Is required for inflammation-induced cell migration and invasion. Cancer Cell 2009, 15(5):416-428.
41. Wu Y., Zhou B.P. Snail: more than EMT. Cell Adhes. Migration 2010, 4(2):199-203.